Peruzzi, Elena Posocco, Bianca Gerratana, Lorenzo Nuti, Margherita Orleni, Marco Gagno, Sara De Mattia, Elena Puglisi, Fabio Cecchin, Erika Toffoli, Giuseppe
...
Published in
Frontiers in Pharmacology
Palbociclib, an oral inhibitor of cyclin-dependent kinase 4 and 6, is approved for the treatment of metastatic breast cancer. This study investigated the influence of diverse clinical and biological factors—age, renal function, genetic variations, and concomitant medications (pharmacokinetic covariates)—on palbociclib pharmacokinetics. Employing a ...
Rugo, Hope S Schmid, Peter Tolaney, Sara M Dalenc, Florence Marmé, Frederik Shi, Ling Verret, Wendy Shah, Anuj Gharaibeh, Mahdi Bardia, Aditya
...
Published in
The oncologist
The TROPiCS-02 study (NCT03901339) demonstrated that sacituzumab govitecan (SG) has superior clinical outcomes over treatment of physician's choice (TPC) chemotherapy in patients with hormone receptor-positive, human epidermal growth factor 2 receptor-negative (HR+/HER2-) metastatic breast cancer (mBC). Here, we present health-related quality of li...
Rugo, Hope Schmid, Peter Tolaney, Sara Dalenc, Florence Marmé, Frederik Shi, Ling Verret, Wendy Shah, Anuj Gharaibeh, Mahdi Bardia, Aditya
...
BACKGROUND: The TROPiCS-02 study (NCT03901339) demonstrated that sacituzumab govitecan (SG) has superior clinical outcomes over treatment of physicians choice (TPC) chemotherapy in patients with hormone receptor-positive, human epidermal growth factor 2 receptor-negative (HR+/HER2-) metastatic breast cancer (mBC). Here, we present health-related qu...
Zhang, Q-Y Cai, R-G Song, G-H Li, C-J Zhang, B-H Kang, X-Y Li, H-P Xu, B-H
Published in
ESMO open
QL1701 is a proposed biosimilar to the reference trastuzumab (Herceptin®). This trial compared the efficacy and safety of QL1701 with the reference trastuzumab in first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. This randomized, double-blinded, parallel-controlled, phase III equivalence tria...
Tolaney, S M Punie, K Carey, L A Kurian, A W Ntalla, I Sjekloca, N Shah, A Rehnquist, M K Stokes, M Fraeman, K
...
Published in
ESMO open
Until recently, treatment options for patients with hormone receptor-positive/human epidermal growth factor 2-negative (HR+/HER2-) metastatic breast cancer (mBC) and resistance to endocrine therapy were limited to chemotherapy. This real-world study describes treatment patterns and outcomes in patients treated with chemotherapy in the United States...
Valenza, C Trapani, D Bidard, F-C Gligorov, J Cortés, J Turner, N Dalenc, F Penault-Llorca, F Freyer, G Arnedos, M
...
Published in
ESMO open
For patients with hormone receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative (HR+/HER2-) metastatic breast cancer (mBC) progressed on first-line endocrine therapy plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i), fulvestrant, a selective estrogen receptor degrader (SERD) administered intramuscularly, represented th...
Mahtani, Reshma Harpalani, Natasha Yan, Fengting Phiel, Kristen Kovalenko, Iuliia
Published in
Frontiers in Oncology
Background Human epidermal growth factor receptor 2 protein (HER2)-positive (+) metastatic breast cancer (MBC) is an aggressive disease and patients often undergo multiple lines of therapy following HER2 targeted therapies. The most recent National Comprehensive Cancer Network (NCCN) guidelines recommend margetuximab plus chemotherapy as fourth-lin...
Derakshan, Nazanin Taylor, Joanne Chapman, Bethany
Published in
Frontiers in Psychology
We investigated the usefulness of a metastatic (secondary) breast cancer Infographics designed to enhance knowledge about symptoms of metastatic breast cancer in women diagnosed with breast cancer. Women with a primary or metastatic diagnosis of breast cancer who had not been in receipt of the Infographics previously, were sent the Infographics and...
Hester, Anna Henze, Franziska Debes, Anna Marie Schubert, Charlotte Leonie Koenig, Alexander Harbeck, Nadia Wuerstlein, Rachel
Published in
Frontiers in Oncology
Background Since the European approval of CDK4/6 inhibitors in 2016, the treatment of patients with hormone-receptor-positive, HER2-negative metastatic breast cancer has changed significantly. Compared with chemotherapy, endocrine-based therapy has different treatment regimens and is associated with new side effects. Oral therapy aims for optimal d...
Curtaz, Carolin J. Wucherpfennig, Sophia Al-Masnaea, Emad Herbert, Saskia-Laureen Wöckel, Achim Meybohm, Patrick Burek, Malgorzata
Published in
Frontiers in Drug Delivery
Therapy of cerebral diseases such as brain metastatic breast cancer is still challenging. Due to the blood-brain barrier (BBB), a tight barrier that protects the brain and prevents the passage of many drugs, therapeutically sufficient drug concentrations in the brain are often not achieved. Therefore, methods and drugs to manipulate the BBB permeab...
